Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.05M Buy
75,150
+2,619
+4% +$302K 0.29% 64
2025
Q4
$7.64M Sell
72,531
-17,542
-19% -$1.65M 0.22% 73
2025
Q3
$7.55M Sell
90,073
-4,202
-4% -$346K 0.23% 74
2025
Q2
$7.46M Sell
94,275
-35,791
-28% -$2.84M 0.24% 76
2025
Q1
$11.7M Sell
130,066
-200,607
-61% -$18.7M 0.48% 47
2024
Q4
$32.8M Buy
330,673
+10,911
+3% +$1.12M 0.2% 25
2024
Q3
$36.4M Buy
319,762
+8,901
+3% +$1.06M 1.51% 18
2024
Q2
$38.6M Sell
310,861
-3,712
-1% -$478K 1.94% 13
2024
Q1
$40.9M Buy
+314,573
New +$38.8M 1.91% 12

Other funds holding MRK

BNP Paribas's MRK Position: Q1 2026 in Review

BNP Paribas increased its Merck (MRK) stake by 3.6% in Q1 2026, buying an estimated $302K and bringing the position to 75,150 shares worth $9.05M. The position accounts for 0.29% of the portfolio, ranked #64.

BNP Paribas first reported a position in MRK in Q1 2024 and has held it in 9 quarters since. The position peaked at $40.9M in Q1 2024. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • BNP Paribas held 75,150 shares of Merck worth $9.05M as of Q1 2026.
  • BNP Paribas bought 2,619 Merck shares in Q1 2026, an estimated $302K.
  • Merck made up 0.29% of BNP Paribas's portfolio in Q1 2026, its #64 holding.
  • BNP Paribas first reported a position in Merck in Q1 2024 and has held it in 9 quarters since.
  • BNP Paribas's Merck position peaked at $40.9M in Q1 2024.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on BNP Paribas's 13F filing for Q1 2026, filed 12 May 2026.